본문 바로가기
KERD
논문KCI 등재

In Vitro Interactions of Antibiotic Combinations of Colistin, Tigecycline, and Doripenem Against Extensively Drug-Resistant and Multidrug-Resistant Acinetobacter baumannii

강성호|김춘미|박건|최인선|정석훈|최지애|장숙진|문대수|박균철
대한진단검사의학회 (Korean Society For Laboratory Medicine)|2016.03|Annals of Laboratory Medicine|제36권 제2호|pp. 124-130

2

조회

0

다운로드

3

인용

0

참고문헌

키워드

AntagonismTigecyclineAcinetobacter baumanniiColistinSynergismExtensively drug-resistantDoripenem
주제분류병리학

초록

Background: Acinetobacter baumannii infections are difficult to treat owing to the emergence of various antibiotic resistant isolates. Because treatment options are limited for multidrug-resistant (MDR) A. baumannii infection, the discovery of new therapies, including combination therapy, is required. We evaluated the synergistic activity of colistin, doripenem, and tigecycline combinations against extensively drug-resistant (XDR) A. baumannii and MDR A. baumannii. Methods: Time-kill assays were performed for 41 XDR and 28 MDR clinical isolates of A. baumannii by using colistin, doripenem, and tigecycline combinations. Concentrations representative of clinically achievable levels (colistin 2 μg/mL, doripenem 8 μg/mL) and achievable tissue levels (tigecycline 2 μg/mL) for each antibiotic were used in this study. Results: The colistin-doripenem combination displayed the highest rate of synergy (53.6%) and bactericidal activity (75.4%) in 69 clinical isolates of A. baumannii. Among them, thedoripenem-tigecycline combination showed the lowest rate of synergy (14.5%) and bactericidal activity (24.6%). The doripenem-tigecycline combination showed a higher antagonistic interaction (5.8%) compared with the colistin-tigecycline (1.4%) combination. No antagonism was observed for the colistin-doripenem combination. Conclusions: The colistin-doripenem combination is supported in vitro by the high rate of synergy and bactericidal activity and lack of antagonistic reaction in XDR and MDR A. baumannii. It seems to be necessary to perform synergy tests to determine the appropriate combination therapy considering the antagonistic reaction found in several isolates against the doripenem-tigecycline and colistin-tigecycline combinations. These findings should be further examined in clinical studies.

Abstract

Background: Acinetobacter baumannii infections are difficult to treat owing to the emergence of various antibiotic resistant isolates. Because treatment options are limited for multidrug-resistant (MDR) A. baumannii infection, the discovery of new therapies, including combination therapy, is required. We evaluated the synergistic activity of colistin, doripenem, and tigecycline combinations against extensively drug-resistant (XDR) A. baumannii and MDR A. baumannii. Methods: Time-kill assays were performed for 41 XDR and 28 MDR clinical isolates of A. baumannii by using colistin, doripenem, and tigecycline combinations. Concentrations representative of clinically achievable levels (colistin 2 μg/mL, doripenem 8 μg/mL) and achievable tissue levels (tigecycline 2 μg/mL) for each antibiotic were used in this study. Results: The colistin-doripenem combination displayed the highest rate of synergy (53.6%) and bactericidal activity (75.4%) in 69 clinical isolates of A. baumannii. Among them, thedoripenem-tigecycline combination showed the lowest rate of synergy (14.5%) and bactericidal activity (24.6%). The doripenem-tigecycline combination showed a higher antagonistic interaction (5.8%) compared with the colistin-tigecycline (1.4%) combination. No antagonism was observed for the colistin-doripenem combination. Conclusions: The colistin-doripenem combination is supported in vitro by the high rate of synergy and bactericidal activity and lack of antagonistic reaction in XDR and MDR A. baumannii. It seems to be necessary to perform synergy tests to determine the appropriate combination therapy considering the antagonistic reaction found in several isolates against the doripenem-tigecycline and colistin-tigecycline combinations. These findings should be further examined in clinical studies.

참고문헌 (38)

  1. Perez F, "Global challenge of multidrug-resistant Acinetobacter baumannii", Antimicrob Agents Chemother, 51, pp.3471~3484 (2007)
  2. Appleman MD, "In vitro activities of nontraditional antimicrobials against multiresistant Acinetobacter baumannii strains isolated in an intensive care unit outbreak", Antimicrob Agents Chemother, 44, pp.1035~1040 (2000)
  3. Sunenshine RH, "Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization", Emerg Infect Dis, 13, pp.97~103 (2007)
  4. Fishbain J, "Treatment of Acinetobacter infections", Clin Infect Dis, 51, pp.79~84 (2010)
  5. Mera RM, "Acinetobacter baumannii 2002-2008: increase of carbapenem-associated multiclass resistance in the United States", Microb Drug Resist, 16, pp.209~215 (2010)
  6. Higgins PG, "Global spread of carbapenem-resistant Acinetobacter baumannii", J Antimicrob Chemother, 65, pp.233~238 (2010)
  7. Poirel L, "Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology", Clin Microbiol Infect, 12, pp.826~836 (2006)
  8. Maragakis LL, "Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options", Clin Infect Dis, 46, pp.1254~1263 (2008)
  9. Karageorgopoulos DE, "Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence", J Antimicrob Chemother, 62, pp.45~55 (2008)
  10. Gordon NC, "Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance", Int J Antimicrob Agents, 35, pp.219~226 (2010)
  11. Peleg AY, "Acinetobacter baumannii: emergence of a successful pathogen", Clin Microbiol Rev, 21, pp.538~582 (2008)
  12. Park YK, "Independent emergence of colistin-resistant Acinetobacter spp. isolates from Korea", Diagn Microbiol Infect Dis, 64, pp.43~51 (2009)
  13. Cai Y, "Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies", J Antimicrob Chemother, 67, pp.1607~1615 (2012)
  14. Navon-Venezia S, "High tigecycline resistance in multidrug-resistant Acinetobacter baumannii", J Antimicrob Chemother, 59, pp.772~774 (2007)
  15. Pankuch GA, "Activity of doripenem with and without levofloxacin, amikacin, and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii", Diagn Microbiol Infect Dis, 67, pp.191~197 (2010)
  16. Dinc G, "Antimicrobial efficacy of doripenem and its combinations with sulbactam, amikacin, colistin, tigecycline in experimental sepsis of carbapenem-resistant Acinetobacter baumannii", New Microbiol, 38, pp.67~73 (2015)
  17. Principe L, "In vitro activity of doripenem in combination with various antimicrobials against multidrug-resistant Acinetobacter baumannii: possible options for the treatment of complicated infection", Microb Drug Resist, 19, pp.407~414 (2013)
  18. Korean Antimicrobial Resistance Monitoring System, "KARMS", KCDC, ~ (2013)
  19. Lee MJ, "Comparison of rpoB gene sequencing, 16S rRNA gene sequencing, gyrB multiplex PCR, and the VITEK2 system for identification of Acinetobacter clinical isolates", DiagnMicrobiol Infect Dis, 78, pp.29~34 (2014)
  20. Magiorakos AP, "Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance", Clin Microbiol Infect, 18, pp.268~281 (2012)
  21. Clinical and Laboratory Standards Institute, "Performance standards for antimicrobial susceptibility testing, 25th Informational supplement, M100-S25", Clinical and Laboratory Standards Institute, ~ (2015)
  22. Peck KR, "In vitro time-kill studies of antimicrobial agents against blood isolates of imipenem-resistant Acinetobacter baumannii, including colistin- or tigecycline-resistant isolates", J Med Microbiol, 61, pp.353~360 (2012)
  23. Turton JF, "The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii", FEMS Microbiol Lett, 258, pp.72~77 (2006)
  24. Bartual SG, "Development of a multilocus sequence typing scheme for characterization of clinical isolates of Acinetobacter baumannii", J Clin Microbiol, 43, pp.4382~4390 (2005)
  25. Oleksiuk LM, "In vitro responses of Acinetobacter baumannii to two- and three-drug combinations following exposure to colistin and doripenem", Antimicrob Agents Chemother, 58, pp.1195~1199 (2014)
  26. Tan TY, "In vitro antibiotic synergy in extensively drug-resistant Acinetobacter baumannii: the effect of testing by time-kill, checkerboard, and Etest methods", Antimicrob Agents Chemother, 55, pp.436~438 (2011)
  27. Entenza JM, "Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies", Int J Antimicrob Agents, 34, pp.8~ (2009)
  28. Ni W, "In vitro effects of tigecycline in combination with colistin (polymyxin E) and sulbactam against multidrug-resistant Acinetobacter baumannii", J Antibiot, 66, pp.705~708 (2013)
  29. Karaoglan I, "In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic", β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii, 2013, pp.41, 1830~1837
  30. Principe L, "In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii", Ann Clin Microbiol Antimicrob, 8, pp.18~ (2009)
  31. Shields RK, "High mortality rates among solid organ transplant recipients infected with extensively drug-resistant Acinetobacter baumannii: using in vitro antibiotic combination testing to identify the combination of a carbapenem and colistin as an effective treatment regimen", Diagn Microbiol Infect Dis, 70, pp.246~252 (2011)
  32. Shields RK, "Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients", PLoSOne, 7, pp.e52349~ (2012)
  33. Clock SA, "In vitro activity of doripenem alone and in multi-agent combinations against extensively drug-resistant Acinetobacter baumannii and Klebsiella pneumoniae", Diagn Microbiol Infect Dis, 76, pp.343~346 (2013)
  34. O’Hara JA, "Activities of vancomycin-containing regimens against colistin-resistant Acinetobacter baumannii clinical strains", Antimicrob Agents Chemother, 57, pp.2103~2108 (2013)
  35. Dizbay M, "In vitro synergistic activity of tigecycline and colistin against XDR-Acinetobacter baumannii", J Antibiot, 63, pp.51~53 (2010)
  36. Ni W, "In vitro synergy of polymyxins with other antibiotics for Acinetobacter baumannii: a systematic review and meta-analysis", Int J Antimicrob Agents, 45, pp.8~18 (2015)
  37. Bell A, "Antimalarial drug synergism and antagonism: mechanistic and clinical significance", FEMS MicrobiolLett, 253, pp.171~184 (2005)
  38. Watine J, "In vitro quinolone-gentamicin antagonism demonstrated by time-kill and combination experiments with clinical isolates of Enterococcus", J Infect Chemother, 3, pp.55~57 (1997)

관련 논문AI추천

광범위 약제내성 Acinetobacter baumannii 균주에 대한 7가지 항균물질 조합의 상승 효과 평가박건, 강성호, 고영진, 김춘미, 장숙진, 최지예대한임상미생물학회 · Annals of Clinical Microbiology2022 · 제25권 제4호In Vitro Synergistic Effects of Antimicrobial Combinations on Extensively Drug-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii Isolates어영, 송원근, 신희봉, 용동은, 이경원, 이혁민, 정석훈, 홍성근, Kyung Ho Roh대한진단검사의학회 · Annals of Laboratory Medicine2016 · 제36권 제2호In vitro Comparison of Anti-Biofilm Effects against Carbapenem-Resistant Acinetobacter baumannii: Imipenem, Colistin, Tigecycline, Rifampicin and Combinations김우주, 노지윤, 송준영, 정희진대한감염학회 · Infection and Chemotherapy2015 · 제47권 제1호다제내성 Acinetobacter baumannii균에서 Tigecycline과 Colistin 치료 후의 임상 결과 평가최인, 김혜미, 박선희, 최은주한국병원약사회 · 병원약사회지2016 · 제33권 제3호다제내성 Acinetobacter baumannii 균주의 항균제 병합 효과문희원, 이미애대한진단검사의학회 · Annals of Laboratory Medicine2005 · 제25권 제5호A 5-Year Surveillance Study on Antimicrobial Resistance of Acinetobacter baumannii Clinical Isolates from a Tertiary Greek HospitalDiamantis P. Kofteridis, Elpis Mantadakis, George Samonis, Sofia Maraki, Viktoria Eirini Mavromanolaki대한감염학회 · Infection and Chemotherapy2016 · 제48권 제3호

이 간행물의 다른 논문 (20건)

Systematic Classification of Mixed-Lineage Leukemia Fusion Partners Predicts Additional Cancer PathwaysRolf Marschalekpp. 85-100Clinicopathological Implications of Mitochondrial Genome Alterations in Pediatric Acute Myeloid Leukemia신명근, 김혜란, 이준형, 김유나, 백희조, 국훈, 강민구, Michael Szardeningspp. 101-110Synergistic Anti-bacterial Effects of Phellinus baumii Ethyl Acetate Extracts and β-Lactam Antimicrobial Agents Against Methicillin-Resistant Staphylococcus aureus신경섭, 임영훈, 윤봉식, 홍승복, 이만휘, 송형근pp. 111-116Direct Identification and Antimicrobial Susceptibility Testing of Bacteria From Positive Blood Culture Bottles by Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry and the Vitek 2 System박강균, 박동진, 한경자, 박연준, 조성진pp. 117-123Evaluation of Xpert C. difficile, BD MAX Cdiff, IMDx C. difficile for Abbott m2000, and Illumigene C. difficile Assays for Direct Detection of Toxigenic Clostridium difficile in Stool Specimens유선미, 신원창, 신보문pp. 131-137
원문 보기